HDAC6 serves as a biomarker for the prognosis of patients with renal cell carcinoma.
Histone deacetylase 6 (HDAC6) is correlated with poor/better survival from cancers. This study was designed to investigate the correlation between HDAC6 expression and renal cell carcinoma (RCC) patients. A total of 45 fresh RCC samples and 132 paraffin embedded tissues as well as their corresponding adjacent non-tumor tissues were collected by surgical excision. The qRT-PCR, western blotting analysis and immunohistochemically analysis were performed to detect the expression of HDAC6. Kaplan-Meier curves analysis and Cox proportional hazards model were used to analysis patients survivals as well as to adjust stratification factors. The experimental results demonstrated that HDAC6 mRNA expression level was significantly upregulated in RCC tissues compared with adjacent non-tumor tissues, and its expression was correlated with histologic grade and poor overall survival of RCC patients. RCC patients with higher HDAC6 expression showed relative poor survival. Moreover, both HDAC6 expression and histologic grade were correlated with RCC prognosis, and high HDAC6 expression was an independent, poor prognostic factor in patient with RCC. These analyses showed that high HDAC6 expression was an independent, poor prognostic factor in patients with RCC, and HDAC6 could serve as a biomarker of RCCs prognostic and an indicator for RCC progression.